Latest Patents News

Aquirian’s subsidiary TBS Mining Solutions has inked a $4.2 million deal with Papyrus Australia to manufacture biodegradable Collar Keeper® products, marking a significant step in sustainable mining practices.

Papyrus Australia has secured a $4.2 million contract to manufacture biodegradable Collar Keeper® products for the mining sector, marking its shift from R&D to commercial production. The agreement with TBS Mining Solutions sets the stage for sustainable innovation in mining operations.

Amplia Therapeutics reported a $4.18 million half-year loss but bolstered its cash reserves with a $27.6 million capital raise to advance clinical trials of its lead drug narmafotinib, showing encouraging interim data in pancreatic cancer.

Recce Pharmaceuticals has secured a key patent in Hong Kong for its synthetic anti-infectives, reinforcing its intellectual property footprint in Asia and supporting its clinical and commercial ambitions in the region.

Anteris Technologies Global Corp. has filed a Form S-1 registration statement with the SEC to enable resale of shares issued in a recent private placement, marking a key step in advancing its DurAVR transcatheter heart valve system and pivotal clinical trials.

Race Oncology has received a $2.8 million Australian R&D tax refund for FY2025, with further overseas R&D rebates expected, bolstering its clinical development of innovative cancer therapies.

Advanced Innergy Holdings Ltd (ASX, AIH) reported unaudited proforma FY25 results exceeding prospectus forecasts, driven by strong organic growth and the strategic acquisition of Ovun. The company reaffirms its FY26 guidance, supported by a robust orderbook and pipeline.

Temas Resources has completed a major drilling campaign at its La Blache project, targeting key critical minerals while progressing its innovative Regenerative Chloride Leach technology promising significant cost savings.

Critical Resources Limited has significantly expanded its Mavis Lake Lithium Project in Ontario, boosting its landholding by 25% and advancing exploration with promising high-grade lithium intercepts. The company also secured a strategic partnership to evaluate cutting-edge solid-state lithium-ion battery technology, positioning itself for the anticipated lithium market rebound.

Mesoblast Limited forecasts a significant jump in quarterly revenue, driven by strong sales of its FDA-approved cell therapy Ryoncil. The company’s latest update highlights robust growth and ongoing expansion in inflammatory disease treatments.

Acrux Ltd reported a remarkable surge in licensing revenue from its topical generics portfolio alongside a strategic pivot towards innovative drug delivery R&D at its 2025 Annual General Meeting.

Bio-Gene Technology Limited has received a $519,500 R&D tax incentive from the Australian government, supporting its development of innovative bio-insecticides targeting insecticide resistance.